EU policymakers are considering a revision to the EU General Pharmaceutical Legislation at a time when science has never offered more hope to patients. Digitalization is enabling better health outcomes across disease areas. It is important that policymakers in the EU create the best environment for science to thrive.

Digitalization is helping to foster diversity in healthcare research, greater healthcare equity, faster development of new medicines, better diagnosis and treatment of patients, and more personalized care. Discovery and development in medicines is getting faster with advancements in technology. Treatments are getting more targeted and production is becoming more efficient.

Artificial intelligence, or AI, is recasting cancer diagnosis and treatment, with new opportunities for improving earlier detection and better care. Digital health records are helping to map the patient journey using smartphones and cloud-based data capture.

In 20 years working in medicines, Ridwaan Jhetam, SVP, Head of Worldwide Medical, Hematology at Bristol Myers Squibb has seen how digitalization is gradually revolutionizing the ability to detect, diagnose, treat and prevent diseases.

Learn about this radical shift in healthcare - and the policy context that shapes it - in an extended interview with Ridwaan.